Press "Enter" to skip to content

Novartis CEO says U.S. rebate plan will return cash to patients

Novartis AG Chief Executive Vas Narasimhan said his company’s prescription drug prices have been “flat to negative” over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits.

Also Read:   Factbox: Latest on the spread of coronavirus around the world